Verastem Investor Relations Material

Verastem Inc is a development-stage biopharmaceutical company primarily focused on the development and commercialization of new medicines aimed at improving the lives of patients diagnosed with cancer. The company is engaged in advancing a pipeline of novel small-molecule drugs that target critical signaling pathways involved in cancer cell survival and tumor growth. These pathways include RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition, which are central to the company's research and development efforts. The company is headquartered in Needham, Massachusetts, and its shares are listed on the Nasdaq.